Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses
Natalia Aptsiauri, Francisco Ruiz‐Cabello, Federico Garrido
Current Opinion in Immunology (2018) Vol. 51, pp. 123-132
Closed Access | Times Cited: 101

Showing 1-25 of 101 citing articles:

Top 10 Challenges in Cancer Immunotherapy
Priti S. Hegde, Daniel S. Chen
Immunity (2020) Vol. 52, Iss. 1, pp. 17-35
Open Access | Times Cited: 1606
The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
Fernando Souza‐Fonseca‐Guimaraes, Joseph Cursons, Nicholas D. Huntington
Trends in Immunology (2019) Vol. 40, Iss. 2, pp. 142-158
Closed Access | Times Cited: 258
STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation
Takashi Nakamura, Takanori Sato, Rikito Endo, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 7, pp. e002852-e002852
Open Access | Times Cited: 184
Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy
Yanyan Xu, Jingyuan Xiong, Xiyang Sun, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 12, pp. 4327-4347
Open Access | Times Cited: 125
Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy
Hanbing Wang, Baorui Liu, Jia Wei
Cancer Letters (2021) Vol. 517, pp. 96-104
Closed Access | Times Cited: 124
A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer
Sandra Tietscher, Johanna Wagner, Tobias Anzeneder, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 110
Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment
Esther Schoutrop, Lidia Moyano‐Galceran, Stéphanie Lheureux, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 207-223
Open Access | Times Cited: 90
Cancer immune escape: MHC expression in primary tumours versus metastases
Federico Garrido, Natalia Aptsiauri
Immunology (2019) Vol. 158, Iss. 4, pp. 255-266
Open Access | Times Cited: 129
Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges
Aifen Lin, Wei‐Hua Yan
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 122
Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
William R. Strohl, Michael Naso
Antibodies (2019) Vol. 8, Iss. 3, pp. 41-41
Open Access | Times Cited: 112
PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
Mustafa Khasraw, David A. Reardon, Michael Weller, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 20, pp. 5287-5296
Open Access | Times Cited: 110
NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival
Aura Muntasell, Federico Rojo, Sònia Servitja, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 5, pp. 1535-1545
Open Access | Times Cited: 102
Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy
Evelien Schaafsma, Chloe M. Fugle, Xiaofeng Wang, et al.
British Journal of Cancer (2021) Vol. 125, Iss. 3, pp. 422-432
Open Access | Times Cited: 100
The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy
Anastasia Mpakali, Efstratios Stratikos
Cancers (2021) Vol. 13, Iss. 1, pp. 134-134
Open Access | Times Cited: 89
HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy
Per Anderson, Natalia Aptsiauri, Francisco Ruiz‐Cabello, et al.
Cellular and Molecular Immunology (2021) Vol. 18, Iss. 3, pp. 556-565
Open Access | Times Cited: 77
Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
Shuyue Wang, Kun Xie, Tengfei Liu
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 76
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Tilemachos Koutouratsas, et al.
Cancer Treatment Reviews (2022) Vol. 113, pp. 102499-102499
Closed Access | Times Cited: 58
Poly-γ-glutamic acid nanoparticles as adjuvant and antigen carrier system for cancer vaccination
Vahideh Mohammadzadeh, Niloufar Rahiman, Horacio Cabral, et al.
Journal of Controlled Release (2023) Vol. 362, pp. 278-296
Closed Access | Times Cited: 26
Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy
Andreia Maia, Mubin Tarannum, Joana R. Lérias, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 451-451
Open Access | Times Cited: 15
MHC/HLA Class I Loss in Cancer Cells
Federico Garrido
Advances in experimental medicine and biology (2019), pp. 15-78
Closed Access | Times Cited: 65
Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
Daniel Baumann, Tanja Hägele, Julian Mochayedi, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 60
Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy
Giovanni Fucá, Andrea Spagnoletti, Margherita Ambrosini, et al.
ESMO Open (2021) Vol. 6, Iss. 1, pp. 100046-100046
Open Access | Times Cited: 48
The Interplay of Exosomes and NK Cells in Cancer Biology
Inês A. Batista, Sofia Torres Quintas, Sónia A. Melo
Cancers (2021) Vol. 13, Iss. 3, pp. 473-473
Open Access | Times Cited: 45
HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy
Luke Maggs, Ananthan Sadagopan, Ali Sanjari Moghaddam, et al.
Trends in cancer (2021) Vol. 7, Iss. 12, pp. 1089-1101
Open Access | Times Cited: 44
The Challenges of HLA Class I Loss in Cancer Immunotherapy: Facts and Hopes
Natalia Aptsiauri, Federico Garrido
Clinical Cancer Research (2022) Vol. 28, Iss. 23, pp. 5021-5029
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top